Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Jenny J Feng & Daniel Ontaneda. (2017) Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies. Degenerative Neurological and Neuromuscular Disease 7, pages 31-45.
Read now
Read now
Luisa Klotz & Heinz Wiendl. (2013) Monoclonal antibodies in neuroinflammatory diseases. Expert Opinion on Biological Therapy 13:6, pages 831-846.
Read now
Read now
Annika Deiß, Isabel Brecht, Axel Haarmann & Mathias Buttmann. (2013) Treating multiple sclerosis with monoclonal antibodies: a 2013 update. Expert Review of Neurotherapeutics 13:3, pages 313-335.
Read now
Read now
Kenneth P Johnson. (2012) Glatiramer acetate for treatment of relapsing–remitting multiple sclerosis. Expert Review of Neurotherapeutics 12:4, pages 371-384.
Read now
Read now
Articles from other publishers (29)
Juntao Cui, Suhan Zhao, Yinghui Li, Danyang Zhang, Bingjing Wang, Junxia Xie & Jun Wang. (2021) Regulated cell death: discovery, features and implications for neurodegenerative diseases. Cell Communication and Signaling 19:1.
Crossref
Crossref
Ricardo Alonso, Cecilia Quarracino, Bárbara Eizaguirre, Leila Cohen, Berenice Silva, Cecilia Pita, Juan Ignacio Rojas, Agustín Pappolla, Jimena Miguez, Liliana Patrucco, Edgardo Cristiano, Carlos Vrech, Gabriel Volman, Emanuel Silva, Andres Barboza, Norma Deri, Verónica Tkachuk, Gisela Zanga, Dario Tavolini, María Laura Saladino, Geraldine Luetic, María Laura Menichini, Edgar Carnero Contentti, Pablo López, Judith Steinberg, Pablo Divi, Javier Hryb, Amelia Alves Pinheiro, Adriana Carra, María Eugenia Balbuena, Luciana Lázaro, Nora Fernández Liguori & Orlando Garcea. (2020) Clinical and demographic characteristics of primary progressive multiple sclerosis in Argentina: Argentinean registry cohort study (RelevarEM). Neurological Sciences 41:11, pages 3329-3335.
Crossref
Crossref
Pei Liu, Chao Li, Ruixuan Zhang, Qing Tang, Jia Wei, Yan Lu & Pingping Shen. (2019) An ultrasensitive electrochemical immunosensor for procalcitonin detection based on the gold nanoparticles-enhanced tyramide signal amplification strategy. Biosensors and Bioelectronics 126, pages 543-550.
Crossref
Crossref
Tim Spelman, Thomas Frisell, Fredrik Piehl & Jan Hillert. (2017) Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis Journal 24:8, pages 1087-1095.
Crossref
Crossref
Ana Paula Kallaur, Sayonara Rangel Oliveira, Andréa Name Colado Simão, Daniela Frizon Alfieri, Tamires Flauzino, Josiane Lopes, Wildea Lice de Carvalho Jennings Pereira, Caio de Meleck Proença, Sueli Donizete Borelli, Damacio Ramón Kaimen-Maciel, Michael Maes & Edna Maria Vissoci Reiche. (2016) Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability. Molecular Neurobiology 54:4, pages 2950-2960.
Crossref
Crossref
Stefan Bittner, Tobias Ruck, Heinz Wiendl, Oliver M. Grauer & Sven G. Meuth. (2016) Targeting B cells in relapsing–remitting multiple sclerosis: from pathophysiology to optimal clinical management. Therapeutic Advances in Neurological Disorders 10:1, pages 51-66.
Crossref
Crossref
Sven Jarius, Klemens Ruprecht, Ingo Kleiter, Nadja Borisow, Nasrin Asgari, Kalliopi Pitarokoili, Florence Pache, Oliver Stich, Lena-Alexandra Beume, Martin W. Hümmert, Marius Ringelstein, Corinna Trebst, Alexander Winkelmann, Alexander Schwarz, Mathias Buttmann, Hanna Zimmermann, Joseph Kuchling, Diego Franciotta, Marco Capobianco, Eberhard Siebert, Carsten Lukas, Mirjam Korporal-Kuhnke, Jürgen Haas, Kai Fechner, Alexander U. Brandt, Kathrin Schanda, Orhan Aktas, Friedemann Paul, Markus Reindl & Brigitte Wildemann. (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. Journal of Neuroinflammation 13:1.
Crossref
Crossref
Jorge Correale, María I. Gaitán, María C. Ysrraelit & Marcela P. Fiol. (2016) Progressive multiple sclerosis: from pathogenic mechanisms to treatment. Brain, pages aww258.
Crossref
Crossref
Jing Ma, Jin-Tai Yu & Lan Tan. (2014) MS4A Cluster in Alzheimer’s Disease. Molecular Neurobiology 51:3, pages 1240-1248.
Crossref
Crossref
Carolyn D. Doucette, Anna L. Greenshields, Robert S. Liwski & David W. Hoskin. (2015) Piperine blocks interleukin-2-driven cell cycle progression in CTLL-2 T lymphocytes by inhibiting multiple signal transduction pathways. Toxicology Letters 234:1, pages 1-12.
Crossref
Crossref
Hirofumi Ochi. (2014) Mechanism of multiple sclerosis based on the clinical trial results of molecular targeted therapy. Clinical and Experimental Neuroimmunology 5, pages 6-15.
Crossref
Crossref
Joseph M. Cantor. (2014) CD98 is a potential target for ablating B cell clonal expansion and autoantibody in multiple sclerosis. Journal of Neuroimmunology 274:1-2, pages 230-233.
Crossref
Crossref
Christina Caon, Cathy Meyer, Lori Mayer & M. Shelton Smith. (2013) Efficacy and Safety of Alemtuzumab in Multiple Sclerosis and Impact on Nursing Role. International Journal of MS Care 15:4, pages 159-168.
Crossref
Crossref
Yaping Yan, Zichen Li, Guang-Xian Zhang, Mark S. Williams, Gregory B. Carey, Jianke Zhang, Abdolmohamad Rostami & Hui Xu. (2013) Anti-MS4a4B treatment abrogates MS4a4B-mediated protection in T cells and ameliorates experimental autoimmune encephalomyelitis. Apoptosis 18:9, pages 1106-1119.
Crossref
Crossref
Mathias Buttmann, Srini Kaveri & Hans-Peter Hartung. (2013) Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders. Trends in Pharmacological Sciences 34:8, pages 445-457.
Crossref
Crossref
Rodolfo Thomé, Adriel S. Moraes, André Luis Bombeiro, Alessandro dos Santos Farias, Carolina Francelin, Thiago Alves da Costa, Rosária Di Gangi, Leonilda Maria Barbosa dos Santos, Alexandre Leite Rodrigues de Oliveira & Liana Verinaud. (2013) Chloroquine Treatment Enhances Regulatory T Cells and Reduces the Severity of Experimental Autoimmune Encephalomyelitis. PLoS ONE 8:6, pages e65913.
Crossref
Crossref
Naveen Mulakayala, Pallavi Rao, Javed Iqbal, Rakeshwar Bandichhor & Srinivas Oruganti. (2013) Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: A brief overview. European Journal of Medicinal Chemistry 60, pages 170-186.
Crossref
Crossref
Jack P. Antel & Veronique E. Miron. 2013. Myelin Repair and Neuroprotection in Multiple Sclerosis. Myelin Repair and Neuroprotection in Multiple Sclerosis
203
231
.
Thomas F. Benkert, Lena Dietz, Elena M. Hartmann, Ellen Leich, Andreas Rosenwald, Edgar Serfling, Mathias Buttmann & Friederike Berberich-Siebelt. (2012) Natalizumab Exerts Direct Signaling Capacity and Supports a Pro-Inflammatory Phenotype in Some Patients with Multiple Sclerosis. PLoS ONE 7:12, pages e52208.
Crossref
Crossref
Nora Fernández Liguori, Gustavo Seifer, Andres M. Villa & Orlando Garcea. (2012) Fingolimod: un nuevo enfoque en el tratamiento de la esclerosis múltiple. Neurología Argentina 4:3, pages 144-151.
Crossref
Crossref
Gesa Weise & Mathias Buttmann. (2012) Welche Chancen bieten neue MS-Medikamente?. DNP - Der Neurologe und Psychiater 13:4, pages 76-89.
Crossref
Crossref
Ilana B Katz Sand & Stephen Krieger. (2012) Emerging strategies for the treatment of multiple sclerosis. Future Neurology 7:2, pages 193-207.
Crossref
Crossref
Luisa Klotz, Sven G. Meuth & Heinz Wiendl. (2012) Immune mechanisms of new therapeutic strategies in multiple sclerosis—A focus on alemtuzumab. Clinical Immunology 142:1, pages 25-30.
Crossref
Crossref
Hans-Peter Hartung, Helmar C. Lehmann, Bernd C. Kieseier & Richard A. C. Hughes. (2011) Novel treatment for immune neuropathies on the horizon. Journal of the Peripheral Nervous System 16:2, pages 75-83.
Crossref
Crossref
. (2011) Current World Literature. Current Opinion in Neurology 24:3, pages 300-307.
Crossref
Crossref
Stephen Krieger. (2011) Multiple Sclerosis Therapeutic Pipeline: Opportunities and Challenges. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 78:2, pages 192-206.
Crossref
Crossref
Ranjan Dutta & Bruce D. Trapp. (2011) Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Progress in Neurobiology 93:1, pages 1-12.
Crossref
Crossref
Peter Wipfler, Andrea Harrer, Georg Pilz, Katrin Oppermann, Eugen Trinka & Jörg Kraus. (2011) Recent developments in approved and oral multiple sclerosis treatment and an update on future treatment options. Drug Discovery Today 16:1-2, pages 8-21.
Crossref
Crossref
Volker Brinkmann, Andreas Billich, Thomas Baumruker, Peter Heining, Robert Schmouder, Gordon Francis, Shreeram Aradhye & Pascale Burtin. (2010) Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nature Reviews Drug Discovery 9:11, pages 883-897.
Crossref
Crossref